Biosimilars: Eight Is Already More Than Enough For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Division of Therapeutic Proteins has received eight pre-IND and IND applications for biosimilar products, and feels a "tremendous strain."
You may also be interested in...
Biosimilars Development Should Target “Residual Uncertainty,” FDA Says
Agency officials stress their willingness to work with applicants, while an industry expert urges comparative testing in the setting or settings most sensitive to potential differences.
FDA, EMA Seek Biosimilar Pathway Convergence
The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.
FDA, EMA Seek Biosimilar Pathway Convergence
The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.